Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV by Alice Fabarius, Armin Leitner, Andreas Hochhaus, Martin C. Müller, Benjamin Hanfstein, Claudia Haferlach, Gudrun Göhring, Brigitte Schlegelberger, Martine Jotterand, Andreas Reiter, Susanne Jung-Munkwitz, Ulrike Proetel, Juliana Schwaab, Wolf-Karsten Hofmann, Jörg Schubert, Hermann Einsele, Anthony D. Ho, Christiane Falge, Lothar Kanz, Andreas Neubauer, Michael Kneba, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Gabriela M. Baerlocher, Michael Lauseker, Markus Pfirrmann, Joerg Hasford, Susanne Saussele, Rüdiger Hehlmann, and Blood Volume 118(26):6760-6768 December 22, 2011 ©2011 by American Society of Hematology

Consort flow diagram of evaluable patients. Alice Fabarius et al. Blood 2011;118:6760-6768 ©2011 by American Society of Hematology

Frequency of major-route ACAs. Alice Fabarius et al. Blood 2011;118:6760-6768 ©2011 by American Society of Hematology

Cumulative incidences of CCR for patients with t(9;22), t(v;22), and minor- and major-route ACAs estimated by the cumulative incidence function considering competing risks. Cumulative incidences of CCR for patients with t(9;22), t(v;22), and minor- and major-route ACAs estimated by the cumulative incidence function considering competing risks. Alice Fabarius et al. Blood 2011;118:6760-6768 ©2011 by American Society of Hematology

Cumulative incidences of MMR for patients with t(9;22), t(v;22), and minor- and major-route ACAs estimated by the cumulative incidence function considering competing risks. Cumulative incidences of MMR for patients with t(9;22), t(v;22), and minor- and major-route ACAs estimated by the cumulative incidence function considering competing risks. Alice Fabarius et al. Blood 2011;118:6760-6768 ©2011 by American Society of Hematology

PFS in the t(9;22), t(v;22), −Y, and minor- and major-route ACA groups calculated by the Kaplan-Meier method and compared by the log-rank test. PFS in the t(9;22), t(v;22), −Y, and minor- and major-route ACA groups calculated by the Kaplan-Meier method and compared by the log-rank test. Patients were censored at the date of last follow-up. The difference between the standard and the major-route groups was significant at P < .001. Alice Fabarius et al. Blood 2011;118:6760-6768 ©2011 by American Society of Hematology

OS in the t(9;22), t(v;22), and minor- and major-route ACA groups calculated by the Kaplan-Meier method and compared by the log-rank test. OS in the t(9;22), t(v;22), and minor- and major-route ACA groups calculated by the Kaplan-Meier method and compared by the log-rank test. Patients were censored at the last follow-up. The difference between the standard and the major-route groups was significant at P < .001. Alice Fabarius et al. Blood 2011;118:6760-6768 ©2011 by American Society of Hematology